KR20030077902A - Composition of anti-diabetes patient food using silkworm product - Google Patents
Composition of anti-diabetes patient food using silkworm product Download PDFInfo
- Publication number
- KR20030077902A KR20030077902A KR1020020016890A KR20020016890A KR20030077902A KR 20030077902 A KR20030077902 A KR 20030077902A KR 1020020016890 A KR1020020016890 A KR 1020020016890A KR 20020016890 A KR20020016890 A KR 20020016890A KR 20030077902 A KR20030077902 A KR 20030077902A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- added
- silkworm
- silk fibroin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 title description 6
- 235000013305 food Nutrition 0.000 title description 3
- 108010022355 Fibroins Proteins 0.000 claims abstract description 39
- 230000002205 anti-dementic effect Effects 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 4
- 229960003080 taurine Drugs 0.000 claims abstract description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 4
- 239000011718 vitamin C Substances 0.000 claims abstract description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 3
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 3
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 3
- 239000003623 enhancer Substances 0.000 claims abstract description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 3
- 239000000796 flavoring agent Substances 0.000 claims abstract description 3
- 235000019634 flavors Nutrition 0.000 claims abstract description 3
- 235000019264 food flavour enhancer Nutrition 0.000 claims abstract description 3
- 229940010454 licorice Drugs 0.000 claims abstract description 3
- 238000004806 packaging method and process Methods 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 description 32
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 19
- 229960004373 acetylcholine Drugs 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 239000000843 powder Substances 0.000 description 15
- 239000002858 neurotransmitter agent Substances 0.000 description 13
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 11
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 9
- 102000016938 Catalase Human genes 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010039966 Senile dementia Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- -1 salt removal Chemical compound 0.000 description 4
- 230000005062 synaptic transmission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-L 5-[(3-carboxylato-4-nitrophenyl)disulfanyl]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)[O-])=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C([O-])=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-L 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 누에산물을 이용한 항치매환자식의 조성물에 관한 것으로 실크 단백질을 효소 가수분해하여 얻은 분자량 500의 실크 피브로인(silk fibroin)과 5령 3일의 누에를 동결건조한 것을 2:1(w/w)로 혼합한 다음, 이 혼합물 5중량부에 기능 강화제로서 타이로신과 트립토판을 각각 0.2중량부씩 첨가하고, 감초 및 계피 추출물 0.02중량부를 첨가하여 이취를 순화하고, 식미 및 기호 강화제로서 구연산 0.05중량부, 비타민 C 0.05중량부를 첨가하고, 여기에 항피로제로서 타우린 0.1중량부를 첨가ㆍ혼합한 다음, 200 ml의 캔포장으로 조제한다.The present invention relates to a composition of anti-dementia patients using silkworm products, which is obtained by lyophilizing silk fibroin having a molecular weight of 500 and a silkworm of 5 days and 3 days obtained by enzymatic hydrolysis of silk protein, 2: 1 (w / After mixing with w), 0.2 parts by weight of tyrosine and tryptophan were respectively added to 5 parts by weight of the mixture as a function enhancer, and 0.02 parts by weight of licorice and cinnamon extract were added to purify the odor, and 0.05 parts by weight of citric acid as a flavor and flavor enhancer. , 0.05 parts by weight of vitamin C is added, 0.1 parts by weight of taurine as an anti-fatigue agent is added and mixed, and then 200 ml of can packaging is prepared.
Description
본 발명은 누에산물을 이용한 항치매환자식의 조성물에 관한 것이다.The present invention relates to an anti-dementia patient composition using a silkworm product.
WHO보고(1985)에 의해 당뇨병은 인슐린 의존형 당뇨병(type Ⅰ), 인슐린 비의존형 당뇨병(type Ⅱ), 그리고 영양실조성 당뇨병(MRDM)으로 분류된다. 그러나 다행스럽게도 우리나라 당뇨병 환자의 84%가 인슐린 비의존형인 type Ⅱ 당뇨병이다(Lee 등, 1984). 특히 type Ⅱ 당뇨병은 40대 이후의 성인중에서 1) 비만형이고 2) 활동량이 적은 사람이나 3)고혈압의 합병증과 4) 간 기능이상이 있는 사람, 그리고 5) 혈중 중성지질의 함량이 높은 사람에게 많이 발병하는 특징을 갖고 있다.Diabetes is classified by the WHO report (1985) into insulin dependent diabetes (type I), insulin independent diabetes (type II), and malnutrition diabetes (MRDM). Fortunately, 84% of diabetic patients in Korea are type II diabetes, independent of insulin (Lee et al., 1984). Type II diabetes is particularly common among adults in their 40s and older, who are 1) obese and 2) less active, 3) have complications of hypertension, 4) have liver dysfunction, and 5) have high levels of triglycerides in their blood. It has the characteristic to
따라서 특히 합병증으로 해서 난치병으로 알려진 당뇨병과 노인성 치매 예방효과를 가진 환자식의 개발이 요청되고 있는 실정이다.Therefore, in particular, as a complication, the development of a patient formula having a prevention effect on diabetes and senile dementia, known as intractable disease, has been requested.
본 발명은 누에산물인 실크피브로인과 누에분말을 주재로한 항치매환자식을 제공하려는데 있다.An object of the present invention is to provide an antidementia patient food based on silk fibroin and silkworm powder.
먹는 누에관련산물로서 실크 피브로인을 주재로 하고, 여기에 누애분말을 첨가하더라도 실크 피브로인의 분자량이 얼마 크기의 실크 피브로인을 사용할 것인가 하는 것이 문제가 아닐 수 없다. 그래서 누에관련 산물중에서 실크 단백질을 증류수로써 염 제거 등 전처리하고, 단백질 분해효소로서 flavouryme (Novo Co., Denmark)을 1% 농도로 첨가하여 55℃에서 2시간 전후로 가수분해의 시간에 따라 분자량 250, 500 및 1,000의 실크 피브로인(silk fibroin)을 얻는 것이 가장 어려운 과제로서 상당한 기술이 요구된다.In vitro실험을 통해 실크 피브로인의 분자량에 따른 DPPH에 의한 항산화능(표 1)을 통해 분자량 500의 실크 피브로인이 가장 효과적이란 사실을 입증하여 silk fibroin(MW 500)을 주재로 하고, 여기에 누에분말을 2:1(w/w)로 첨가하여 노인성 항치메 환자식을 개발하였다.Silk fibroin is mainly used as a silkworm-related product to be eaten, and even if silkworm powder is added, it is a problem to determine how much silk fibroin to use. Thus, silk protein was pretreated in distilled water, such as salt removal from silkworm-related products, and flavouryme (Novo Co., Denmark) was added at a concentration of 1% as a protease, and molecular weight 250, Obtaining silk fibroins of 500 and 1,000 is the most difficult task and requires considerable skill. In vitro experiments showed that silk fibroin having a molecular weight of 500 was the most effective through the antioxidant activity of DPPH according to the molecular weight of silk fibroin (Table 1), based on silk fibroin (MW 500), and silkworm powder Was added 2: 1 (w / w) to develop an senile antichime patient.
전자공여능(electron donating ability)에 의한 항산화능을 비교하기 위하여 50% 감소되는데 필요한 투여량(μg)을 측정하여 본 결과, 표 1에서 보는 바와 같이 분자량 250의 실크 피브로인(4,774±385 μg : 100%) 대비 분자량 500의 실크 피브로인이 73.6%로서 가장 효과적임을 알 수 있었다.As a result of measuring the dose (μg) required to reduce 50% in order to compare the antioxidant capacity by electron donating ability, silk fibroin (4,774 ± 385 μg: 100%) having a molecular weight of 250 as shown in Table 1 The silk fibroin having a molecular weight of 500 was 73.6%, which is the most effective.
실크 피브로인(silk fibroin)은 누에 단백질의 가수분해산물로서 먹는 누에로서의 기능성 생리활성을 갖는 성분으로서 자리 매김하고 있다. 실크 피브로인은 노인성 치매의 치료 및 예방과 밀접한 관련이 있는 신경전달물질인 아세틸콜린(acetylcholinc : ACh)과 관련효소로서 ACh의 합성효소(choline acetyltransferase : ChAT) 및 신경전달에 관계하는 ACh의 분해효소(acetylcholineesterase : AChE), 그리고 카테콜아민(catecholamine)계 신경전달물질파괴효소로서 monoamine oxidase-B (MAO-B)의 활성 억제에 미치는 효과, 그리고 활성산소 등의 생성 억제 효과 등에 미치는 영향을 평가하고, 다시 누에분말의 노화억제효과 등 분석하여 노인성 치매예방 환자식의 조성물을 구성하였다.Silk fibroin is positioned as a component having functional physiological activity as a silkworm to be eaten as a hydrolyzate of silkworm protein. Silk fibroin is a neurotransmitter (acetylcholinc (ACh)) and related enzymes that are closely related to the treatment and prevention of senile dementia. Acetylcholineesterase (AChE) and catecholamine-based neurotransmitter breakdown enzymes were evaluated for their effects on the inhibition of the activity of monoamine oxidase-B (MAO-B) and the inhibitory effects on the production of free radicals. The antiaging effect of the powder was analyzed to form a composition for preventing dementia.
본 발명은 신경전달물질 및 관련효소의 활성 증가로 치매의 예방효과가 인정된 실크 피브로인(silk fibroin)과 노화의 억제효과가 뛰어난 누에분말(silkworm powder)을 2:1(w/w)로 혼합하고, 이 혼합물 1.0∼5.0 중량부에 식미(食味) 개선제로서 타이로신과 트립토판 각각 0.5중량부, 타우린 0.1중량부, 비타민 C, 및 구연산을 각각 0.05중량부를 Greenbia mild care(MC)에 첨가ㆍ제조한 200 ml들이 노인성 항치매환자식(Anti-dementia Patient Food)를 제조하였다.The present invention is a 2: 1 (w / w) mixed with silk fibroin (silkworm powder) excellent in inhibiting aging and silk fibroin is recognized to prevent dementia by increasing the activity of neurotransmitters and related enzymes 1.0 to 5.0 parts by weight of this mixture was prepared by adding 0.5 parts by weight of tyrosine and tryptophan, 0.1 part by weight of taurine, vitamin C, and citric acid to 0.05 parts by weight of Greenbia mild care (MC), respectively. 200 ml of Anti-dementia Patient Food was prepared.
본 항치매 환자식 개발을 위하여in vivo실험을 실시한 실험재료, 실험방법 및 실험결과는 다음과 같다.Experimental materials, experimental methods and results of in vivo experiments for the development of the antidementia patient formula are as follows.
1. 동물실험 및 사료조성1. Animal testing and feed composition
(1) 사용동물 및 실험(1) Animals and experiment
Biogenomics사(서울)에서 구입한 Crj/Bgi계 랫트(male, 180±10 g)를 동물사육실에서 2주동안 예비사육한 다음, 7마리씩 4군으로 나누어 대조군(control group)은 실크 피브로인-누에분말(2:1, w/w)을 첨가하지 않은 Greenbia mild care(MC)만을, 그리고 실험군에는 Greenbia MC에 실크 피브로인-누에분말(2:1, w/w)을 각각 1.0%. 3.0% 및 5.0%를 첨가ㆍ제조한 200 ml들이 노인성 항치매환자식을 4주 동안 투여하여 신경전달물질의 생성 및 관련효소의 활성 등을 평가하여 노인성 항치매환자식을 조성하였다. 동물사육실은 항온항습(22±2℃, 65±2% RH)하에서 12시간 싸이클(06:00∼18:00)로 명암이 자동조절된다.Crj / Bgi rats (male, 180 ± 10 g) purchased from Biogenomics (Seoul) were preliminarily bred for two weeks in an animal nursery, and then divided into four groups of seven animals. The control group was silk fibroin- silkworm powder. Greenbia mild care (MC) only without (2: 1, w / w) and silk fibroin- silkworm powder (2: 1, w / w) in Greenbia MC were 1.0%, respectively. The 200 ml of 3.0% and 5.0% added senile anti-dementia patients were administered for 4 weeks to evaluate the production of neurotransmitters and related enzymes. The animal breeding room is automatically controlled with a 12-hour cycle (06: 00-18: 00) under constant temperature and humidity (22 ± 2 ℃, 65 ± 2% RH).
(2) 노인성 항치매환자식의 조성(2) The furtherance of senile antidementia patient meal
본 실험에 사용한 사료조성은 탄수화물로서 말토덱스트린(maltodextrin) 29 g, 지질로서 해바라기 기름 및 MCT oil 6.0 g, 단백질로서 카제인나트륨(sodium caseinate) 및 대두 단백질(spoybean protein) 7.5 g을 혼합하고, 여기에 비타민으로서 A(77.78 μgRE), D3(0.56 μg), E(1.12 mgα-TE), C(6.12 mg), Folic acid(27.78 μg), Niacin(1.89 mg NE), Biotin(7.78 μg)과 무기질로서 Ca(90 mg), P(90 mg), Fe(1.34 mg), Mg (38.89 mg), K(254 mg), Na(149 mg)을 첨가하였다. 이것을 200 ml들이 캔으로 만들어 전체 에너지량은 200 kcal가 되도록 조제하여 노인성 항치매환자식으로 한다.The feed composition used in this experiment was mixed with 29 g maltodextrin as carbohydrate, 6.0 g sunflower oil and MCT oil as lipid, 7.5 g sodium caseinate and 7.5 g soy protein as protein. Vitamins A (77.78 μgRE), D 3 (0.56 μg), E (1.12 mgα-TE), C (6.12 mg), Folic acid (27.78 μg), Niacin (1.89 mg NE), Biotin (7.78 μg) and minerals Ca (90 mg), P (90 mg), Fe (1.34 mg), Mg (38.89 mg), K (254 mg), Na (149 mg) were added. 200 ml of this can is prepared so that the total amount of energy is 200 kcal.
2. 실 험 재 료2. Experimental materials
(1) 항치매환자식의 조성을 위한 재료(1) Materials for the composition of antidementia patients
실크 단백질을 증류수로써 염 제거 등 전처리하고, 단백질 분해효소로서 flavouryme(Novo Co., Denmark)을 1% 농도로 첨가하여 55℃에서 2시간 전후로 가수분해의 시간에 따라 분자량 250, 500 및 1,000의 실크 피브로인 중에서 표 1의 실험에서 가장 생리활성이 좋은 분자량 500의 실크 피브로인(Silk fibroin)과 5주 3령의 누에를 동결건조하여 얻은 누에분말을 2:1(w/w)의 비율로 혼합하고, 이 혼합물을 1.0%, 3.0% 및 5.0%가 되도록 Greenbia DM에 첨가하여 물로써 200 ml가 되도록 혼합ㆍ조제하였다.Pretreatment of silk protein with distilled water, such as salt removal, and addition of flavouryme (Novo Co., Denmark) at a concentration of 1% as a protease, silk at molecular weights of 250, 500 and 1,000 depending on the time of hydrolysis at 55 ° C for 2 hours. Among the fibroins, silk fibroin having a molecular weight of 500 with the highest bioactivity in the experiment of Table 1 and silkworm powder obtained by lyophilization of silkworms at 5 weeks of age were mixed at a ratio of 2: 1 (w / w), This mixture was added to Greenbia DM to 1.0%, 3.0% and 5.0%, and mixed and prepared to 200 ml with water.
(2) 사용시약(2) Reagent
본 실험에 사용한 시약으로서 acetylcholine(ACh), choline acetyl transferase(ChAT) 등의 시약, 그밖의 분석용 시약은 모두 Sigma제 특급시약을 사용하였다.As reagents used in this experiment, reagents such as acetylcholine (ACh) and choline acetyl transferase (ChAT), and other analytical reagents, all used special reagents made by Sigma.
3. 실 험 방 법3. Experimental method
(1) 항치매 환자식의 투여(1) Administration of antidementia patient meal
Crj/Bgi계 랫트(male, 180 g)에 Greenbia diabetes millitus의 기재에 실크 피브로인(silk fibroin : SF)과 누에분발(silkworm powder : SWP)의 혼합물(SF-SWP 2:1, w/w)을 각각 1.0%, 3.0%, 5.0%가 되도록 첨가하여 200 ml의 캔으로 만든 노인성 항치매 환자식을 물병에 넣어 4주 동안 자유 섭취시킨 다음, 활성산소의 억제 및 신경전달물질 및 관련효소를 측정하여 항치매 방지효과를 평가하였다. 그러나, 랫트(체중 200 g)가 하루에 20 ml정도의 음료수를 섭취하기 때문에 하루에 항치매환자식중의 실크 피브로인과 누에분말의 혼합물의 하루 섭취량은 각자 100, 300 및500 mg에 해당된다.Crj / Bgi rats (male, 180 g) were treated with a mixture of silk fibroin (SF) and silkworm powder (SWP) on a substrate of Greenbia diabetes millitus (SF-SWP 2: 1, w / w). Addition of 1.0%, 3.0%, and 5.0%, respectively, into a bottle of senile anti-dementia patients made from 200 ml of cans, followed by free intake for 4 weeks, inhibition of free radicals and measurement of neurotransmitters and related enzymes. The antidementia effect was evaluated. However, since rats (200 g body weight) consume about 20 ml of liquid per day, the daily intake of a mixture of silk fibroin and silkworm powder in antidementia patients per day corresponds to 100, 300 and 500 mg, respectively.
(2) 히드록시 라디칼(OH) 및 산화 단백질의 측정(2) Determination of hydroxy radicals (OH) and oxidized proteins
활성산소중에서 가장 강력한 hydroxyl radical (ㆍOH)의 생성량은 Chan 등(1976)의 방법에 따라 정량하였고, 산화적 스트레스로서 활성산소의 공격에 의한 산화 단백질(oxidized protein : OP)의 생성은 Levine 등(1990)의 방법에 따라 carbonyl group의 생성량을 측정하여 정량하였다.The production of the most powerful hydroxyl radical (OH) among free radicals was quantified according to the method of Chan et al. (1976), and the production of oxidized protein (OP) by the attack of free radicals by oxidative stress is Levine et al. According to the method of 1990), the amount of carbonyl group was measured and quantified.
(3) 제거효소의 활성 측정(3) Determination of activity of the eliminating enzyme
생체내의 모든 호기적 세포에 존재하고 있는 활성산소의 scavenger enzymes로서 가장 중요한 수퍼옥시드 디스무타아제(superoxide dismutase: SOD)의 활성은 Oyanagui 등(1984)의 방법에 따라 측정하여 정량하였고, 카탈라아제(catalase : CAT)의 활성은 Rigo 등(1997)의 방법에 따라 측정하여 정량하였다.The activity of superoxide dismutase (SOD), the most important free radical scavenger enzymes present in all aerobic cells in vivo, was measured and quantified according to the method of Oyanagui et al. (1984), and catalase : CAT) activity was measured and quantified according to the method of Rigo et al. (1997).
(4) 아세틸콜린(ACh) 및 관련효소 측정(4) measuring acetylcholine (ACh) and related enzymes
아세틸콜린(acetylcholine : ACh)의 측정은 Hestrin 등(1949)의 방법에 의하여 alkaline hydroxylamine을 가진 O-acyl 유도물의 반응을 기초로 측정하였고, 뇌세포의 콜린 아세틸트란스퍼라아제(choline acetyltransferase: ChAT)의 측정은 Ellman(1959)의 방법에 따라 0.2mM accetyl-CoA, 10mM choline chloride, 0.2M KCl , 10mM potassium phosphate with 1mM EDTA를 각각 0.2㎖씩 첨가ㆍ혼합하여 총 0.8㎖의 부피로 만든 다음 choline acetyltransferase을 1㎕, cytosol 100㎕, 1M tris buffer 190㎕, DTB(5,5'-dithiobis-2-nitro- benzoate)를 5㎕, 20% TCA (trichloroacetic acid) 250㎕의 양으로 각각 첨가ㆍ혼합하여 분광광도계를 이용해파장 412nm에서 2분 간격으로 ChAT의 활성을 측정하였다.Acetylcholine (ACh) was measured based on the reaction of O-acyl derivatives with alkaline hydroxylamine by the method of Hestrin et al. (1949), and of choline acetyltransferase (ChAT) in brain cells. The measurement was performed by adding and mixing 0.2 ml of 0.2 mM accetyl-CoA, 10 mM choline chloride, 0.2 M KCl, and 10 mM potassium phosphate with 1 mM EDTA to the total volume of 0.8 ml according to the method of Ellman (1959), and then choline acetyltransferase was added. Add 1 μl, 100 μl of cytosol, 190 μl of 1M tris buffer, and 5 μl of DTB (5,5'-dithiobis-2-nitrobenzoate) in 5 μl and 250 μl of 20% TCA (trichloroacetic acid). Using a photometer, the activity of ChAT was measured at a wavelength of 412 nm at 2 minute intervals.
4. 실험결과의 평가4. Evaluation of Experimental Results
(1) 활성산소 및 산화적 스트레스 억제효과(1) inhibitory effect on free radicals and oxidative stress
실크 피브로인-누에분말 혼합물(2:1, w/w)을 기재 Greenbia MC에 1.0%, 3.0%, 5.0%를 첨가하여 조제한 200 ml들이 캔포장한 항치매 환자식을 물병에 넣어 Crj/Bgi 랫트에 4주동안 투여하여 활성산소 및 산화적 스트레스에 미치는 영향을 분석하여 본 결과는 표 2와 같다. 가장 강력한 활성산소인 히드록시 라디칼(ㆍOH)의 생성도 매우 효과적으로 억제할 수 있을 뿐만 아니라 활성산소의 공격에 의한 산화 단백질의 생성도 매우 효과적으로 억제할 수 있음을 알 수 있었다. 따라서 신경전달물질의 손상 방지는 물론이고 성인병이나 노화까지 매우 효과적으로 억제할 가능성이 기대된다.Crj / Bgi rats containing 200 ml canned anti-dementia patients prepared by adding 1.0%, 3.0%, and 5.0% of silk fibroin-silk powder mixture (2: 1, w / w) to Greenbia MC. The results of the analysis on the effects of free radicals and oxidative stress on administration for 4 weeks are shown in Table 2. It was found that not only can the production of hydroxy radicals (.OH), the most powerful active oxygen, be inhibited very effectively, but also the production of oxidized proteins due to the attack of active oxygen can be suppressed very effectively. Therefore, as well as preventing the damage of neurotransmitters is expected to be very effective in inhibiting adult diseases and aging.
SFㆍSWP-1.0, 3.0, 5.0투여군 : 하루 실제 실크 피브로인(SF)-누에분말(SWP) 100, 300, 500 mg 섭취량;SF. SWP-1.0, 3.0, 5.0 administration group: daily silk fibroin (SF)-silkworm powder (SWP) 100, 300, 500 mg intake;
a평균치±SD;b대조군 대비(%); 유의성 검정 : 대조그룹 대비*p<0.05;**p<0.01;***p<0.001. a mean ± SD; b % of control; Significance test: compared with control group * p <0.05; ** p <0.01; *** p <0.001.
(2) 활성산소 제거효소의 활성 평가(2) Evaluation of activity of free radical scavenger
개발 항치매환자식을 물병에 넣어 Crj/Bgi 랫트에 4주동안 투여하여 활성산소에 대한 제거효소의 활성을 비교하여 본 결과는 표 3과 같다.Developmental dementia patients were placed in a water bottle and administered to Crj / Bgi rats for 4 weeks to compare the activity of scavenging enzymes against free radicals.
가장 강력한 활성산소인 활성산소의 제거효소로서 수퍼옥사이드 디스뮤타아제(SOD)의 활성에 미치는 영향은 SFㆍSWP-3.0 및 SFㆍSWP-5.O 투여군의 Cu/Zn-SOD 활성은 각각 2.88±0.23, 3.06±0.09 U/mg protein으로서 대조군의 Cu/Zn-SOD 활성(2.59±0.08 U/mg protein : 100%) 대비 각각 12 및 18%의 매우 유의적인 활성산소 제거효소의 효과가 인정되었다.The effect of superoxide dismutase (SOD) activity on the active oxygen scavenging enzyme, the most powerful active oxygen, was found to be 2.88 ± Cu / Zn-SOD activity of SF.SWP-3.0 and SF.SWP-5.O group. As the 0.23, 3.06 ± 0.09 U / mg protein, the effect of 12 and 18% of the active oxygen scavenging enzyme of 12 and 18%, respectively, compared to the Cu / Zn-SOD activity of the control group (2.59 ± 0.08 U / mg protein: 100%) was recognized.
또한 체내 대사과정중에 생성되는 활성산소로서 히드록시 라디칼이나 과산화수소 등의 활성산소 제거효소로서 카탈라아제(CAT)의 활성에 미치는 영향으로서 SFㆍSWP-3.0 및 SFㆍSWP-5.0 투여군의 CAT 활성은 각각 1.10±0.08, 1.12±0.04 μmol/ml serum으로서 대조군의 CAT의 활성(0.95±0.01 μmol/ml serum : 100%) 대비 각각 16및 18%의 매우 유의적인 활성산소 제거효소의 활성이 인정되었다. 따라서 이들 항치매환자식의 개발은 활성산소의 억제 및 scavenger enzyme의 활성 증가로 성인병을 억제하고 노화를 방지할 수 있을 뿐만 아니라 신경전달물질의 손상을 효과적으로 방지함으로써 노인성 치매도 효과적으로 방지할 수 있을 것으로 기대된다.In addition, the effects of catalase (CAT) activity on the activity of catalase (CAT) as active oxygen scavenging enzymes such as hydroxy radicals and hydrogen peroxide, etc. As the ± 0.08 and 1.12 ± 0.04 μmol / ml serum, 16 and 18% of the significant active oxygen scavenging enzyme activities were recognized, respectively, compared to the CAT activity of the control group (0.95 ± 0.01 μmol / ml serum: 100%). Therefore, the development of these anti-dementia patients will not only prevent adult disease and prevent aging by inhibiting free radicals and increasing the activity of scavenger enzyme, but also effectively prevent senile dementia by effectively preventing neurotransmitter damage. It is expected.
SFㆍSWP-1.0, 3.0, 5.0투여군 : 하루 실제 실크 피브로인(SF)-누에분말(SWP) 100, 300, 500mg 섭취량;SF.SWP-1.0, 3.0, 5.0 administration group: 100, 300, 500 mg intake of silk fibroin (SF) -silk powder (SWP) per day;
a평균치±SD;b대조군 대비(%); 유의성 검정 : 대조그룹 대비*p<0.05;**p<0.01;***p<0.001. a mean ± SD; b % of control; Significance test: compared with control group * p <0.05; ** p <0.01; *** p <0.001.
(3) 신경전달물질 및 관련효소의 활성 평가(3) Evaluation of the activity of neurotransmitters and related enzymes
개발 항치매환자식을 물병에 넣어 Crj/Bgi 랫트에 4주동안 투여하여 주요 신경전달물질인 아세틸콜린(acetylcholine : ACh)의 합성량, ACh의 합성효소로서 콜린 아세틸트란스퍼라아제(choline acetyltransferase : ChAT), 그리고 신경전달에 직접 관계하는 아세틸콜린에스터라아제(acetylcholinesterase : ACHE)의 활성을 비교ㆍ평가하여 본 결과는 표 4와 같다.Developmental dementia patients were placed in water bottles and administered to Crj / Bgi rats for 4 weeks to synthesize acetylcholine (ACh), a major neurotransmitter, and choline acetyltransferase (CHAT) as a synthase of ACh. ) And the activity of acetylcholinesterase (ACHE) directly related to neurotransmission.
항치매환자식으로서 SFㆍSWP-3.0 및 SFㆍSWP-5.0 투여군의 ACh의 합성량은 각각 39.35±1.95, 40.12±2.90 U/mg protein으로서 대조군의 ACh의 합성량(36.04±2.19 ng/mg protein : 100%) 대비 각각 9.2% 및 12.3%의 매우 유의적인 ACh의 합성량 증가효과가 인정되었다. 또한 ACh의 합성효소로서 ChAT의 활성은 용량의존적으로 증가하고 있었으나 유의성은 SFㆍSWP-5.0투여군에서만 대조군 대비 12.5%의 매우 효과적인 ACh의 합성효소 ChAT의 활성 증가효과가 인정되었다. 한편 이들 항치매환자식 SFㆍSWP투여군의 신경전달에 직접 관계하는 AChE의 활성에 미치는 영향도 SFㆍSWP투여군의 용량 의존적으로 AChE의 활성이 증가하였는데, 특히 SFㆍSWP-5.0 투여군의 AChE의 활성은 대조군 대비 약 10%나 유의적으로 AChE의 활성 증가효과가 인정되었다.The amount of ACh synthesized in the SF, SWP-3.0 and SF.SWP-5.0 administration groups as antidementia patients was 39.35 ± 1.95 and 40.12 ± 2.90 U / mg protein, respectively, and the amount of ACh in the control group (36.04 ± 2.19 ng / mg protein). : Significantly increased the amount of ACh synthesis of 9.2% and 12.3%, respectively. In addition, the activity of ChAT as a synthase of ACh was increased in dose-dependent manner, but the significance was significantly increased by 12.5% of ACh synthase ChAT activity compared to the control group only in SF.SWP-5.0 administration group. On the other hand, the effect of AChE directly related to neurotransmission in the antidementia patient SF / SWP group also increased AChE activity in a dose-dependent manner of the SF / SWP group, especially the activity of AChE in the SF / SWP-5.0 group. The activity of AChE was significantly increased by about 10% compared to the control group.
이들 항치매환자식의 개발은 활성산소나 산화적 스트레스의 억제효과 및 scavenger enzyme으로서 제거효소의 활성 증가효과 뿐만 아니라 신경전달물질의 합성을 통한 신경전달의 효과적인 발현을 통해 노인성 치매를 효과적으로 예방할 수 있을 뿐만 아니라 신경전달을 촉진할 수 있다는 사실이 입증되었다. 따라서 노인성 항치매환자식이 성인병과 노화를 방지할 수 있을 뿐만 아니라 노인성 치매도 매우 효과적으로 방지할 수 있을 것으로 기대된다.The development of these anti-dementia patients can effectively prevent senile dementia through the effective expression of neurotransmitter through the synthesis of neurotransmitters as well as the effect of inhibiting free radicals and oxidative stress and increasing the activity of scavenger enzyme. In addition, it has been demonstrated that it can promote neurotransmission. Therefore, it is expected that the anti-dementia patients may not only prevent adult disease and aging, but also effectively prevent senile dementia.
신경전달물질ACh 및 관련효소의 활성에 미치는 항치매환자식의 투여효과Effect of Antidementia Patients on the Neurotransmitter ACh and Related Enzymes
SFㆍSWP-1.0, 3.0, 5.0투여군 : 하루 실제 실크 피브로인(SF)-누에분말(SWP) 100, 300, 500mg 섭취량;SF.SWP-1.0, 3.0, 5.0 administration group: 100, 300, 500 mg intake of silk fibroin (SF) -silk powder (SWP) per day;
a평균치±SD;b대조군에 대한 %; 유의성 검정 : 대조그룹 대비*p<0.05;**p<0.01. a mean ± SD; b % of control group; Significance test: compared with control group * p <0.05; ** p <0.01.
실시예 1Example 1
실크 단백질을 효소 가수분해하여 얻은 분자량 500의 실크 피브로인(silk fibroin)과 5령 3일의 누에를 동결건조하여 2:1(w/w)로 혼합한 다음, 이 혼합물 5중량부에 기능 강화제로서 타이로신과 트립토판을 각각 0.2중량부씩 첨가하고, 감초 및 계피 추출물 0.02중량부를 첨가하여 이취를 순화하고, 식미 및 기호 강화제로서 구연산 0.05중량부, 비타민 C 0.05중량부를 첨가하고, 여기에 항피로제로서 타우린 0.1중량부를 첨가ㆍ혼합한 다음, 200 ml의 캔포장으로 기능성 항치매환자식을 제조하였다.Silk fibroin of molecular weight 500 obtained by enzymatic hydrolysis of silk protein and silkworm of 5 days and 3 days were lyophilized and mixed at 2: 1 (w / w), and then, 5 parts by weight of the mixture was used as a function enhancer. 0.2 parts by weight of tyrosine and tryptophan were respectively added, and 0.02 parts by weight of licorice and cinnamon extract were added to purify the odor, and 0.05 parts by weight of citric acid and 0.05 parts by weight of vitamin C were added as a flavor and flavor enhancer, and taurine as an anti-fatigue agent was added thereto. After 0.1 parts by weight was added and mixed, a functional anti-dementia patient was prepared in 200 ml of can packaging.
본 발명은 삶의 질을 저하하는 가장 중요한 원인인 노인성 치매를 예방하고 방지할 수 있는 항치매환자식을 조성하기 위하여 실크 피브로인(silk fibroin)의 신경전달물질중에서 가장 중요한 아세틸콜린(acetylcholine : ACh)과 관련효소로서 합성효소인 콜린아세틸트란스퍼라아제(choline acetyltransferase : CAhT) 및 신경전달에 직접 관계하는 아세틸롤린에스터라아제(acetylcholinesterase : AChE)의 활성 증가효과를 중심으로 하고 여기에 누에분말(silkworm powder)의 성인병 및 노화의 억제효과를 접목해서 노인성 항치매환자식을 제조하였기 때문에 본 발명의 음료를 마시면 치매환자, 당뇨환자의 건강에 유효하다.The present invention is the most important acetylcholine (acetylcholine (ACh) among the neurotransmitters of silk fibroin (silk fibroin) in order to create an anti-dementia patient that can prevent and prevent the dementia of the elderly, the most important cause of poor quality of life As a related enzyme, choline acetyltransferase (CAhT), a synthetase, and acetylcholinesterase (AChE), which are directly involved in neurotransmission, are mainly used for silkworm powder. Since the anti-dementia patient formula was prepared by combining geriatric disease and the inhibitory effect of aging, the beverage of the present invention is effective for the health of dementia patients and diabetics.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020016890A KR20030077902A (en) | 2002-03-27 | 2002-03-27 | Composition of anti-diabetes patient food using silkworm product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020016890A KR20030077902A (en) | 2002-03-27 | 2002-03-27 | Composition of anti-diabetes patient food using silkworm product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030077902A true KR20030077902A (en) | 2003-10-04 |
Family
ID=32376914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020020016890A Ceased KR20030077902A (en) | 2002-03-27 | 2002-03-27 | Composition of anti-diabetes patient food using silkworm product |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20030077902A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100528740B1 (en) * | 2002-04-02 | 2005-11-15 | 부경대학교 산학협력단 | Made of anti-hangover beverage using silk fibroin |
| WO2006014033A1 (en) | 2004-07-31 | 2006-02-09 | Brainguard Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
| WO2012020991A3 (en) * | 2010-08-11 | 2012-05-24 | 월드웨이㈜ | Composition for preventing and alleviating brain disease comprising silk amino acid and tyrosine as active ingredients |
| KR20190017271A (en) * | 2017-08-10 | 2019-02-20 | 유병혁 | Development of functional herbal drink using silkworm and Cinnamommum cassia extract |
| KR20190133457A (en) * | 2018-05-23 | 2019-12-03 | 대한민국(농촌진흥청장) | Composition for improving memory or composition for preventing and treating Alzheimer's dementia containing boiled silkworm products having silk protein |
| US11357810B2 (en) | 2019-10-09 | 2022-06-14 | Brain Health Holding Llc | Compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil having synergistic effects for improving memory, focus, and cognitive function, and related methods |
| US11707497B2 (en) | 2019-10-09 | 2023-07-25 | Brain Health Holding Llc | Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states |
-
2002
- 2002-03-27 KR KR1020020016890A patent/KR20030077902A/en not_active Ceased
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100528740B1 (en) * | 2002-04-02 | 2005-11-15 | 부경대학교 산학협력단 | Made of anti-hangover beverage using silk fibroin |
| WO2006014033A1 (en) | 2004-07-31 | 2006-02-09 | Brainguard Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
| EP1773864A4 (en) * | 2004-07-31 | 2009-02-18 | Biogrand Co Ltd | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
| AU2004322006B2 (en) * | 2004-07-31 | 2012-05-24 | Brainguard Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
| US10010574B2 (en) | 2004-07-31 | 2018-07-03 | Brainguard Co., Ltd. | Silk peptide for improving neuroprotective and neurofunctional effects and a method of its preparation |
| WO2012020991A3 (en) * | 2010-08-11 | 2012-05-24 | 월드웨이㈜ | Composition for preventing and alleviating brain disease comprising silk amino acid and tyrosine as active ingredients |
| KR20190017271A (en) * | 2017-08-10 | 2019-02-20 | 유병혁 | Development of functional herbal drink using silkworm and Cinnamommum cassia extract |
| KR20190133457A (en) * | 2018-05-23 | 2019-12-03 | 대한민국(농촌진흥청장) | Composition for improving memory or composition for preventing and treating Alzheimer's dementia containing boiled silkworm products having silk protein |
| US11357810B2 (en) | 2019-10-09 | 2022-06-14 | Brain Health Holding Llc | Compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil having synergistic effects for improving memory, focus, and cognitive function, and related methods |
| US11707497B2 (en) | 2019-10-09 | 2023-07-25 | Brain Health Holding Llc | Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states |
| US12194071B2 (en) | 2019-10-09 | 2025-01-14 | Brain Health Holding Llc | Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6447772B1 (en) | Compositions and methods relating to reduction of symptoms of autism | |
| US10016450B2 (en) | Anti-glycation methods and compositions | |
| US6251391B1 (en) | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons | |
| Premalatha et al. | Semecarpus anacardium L. nut extract administration induces the in vivo antioxidant defence system in aflatoxin B1 mediated hepatocellular carcinoma | |
| AU2017320520B2 (en) | Use of collagen hydrolysate for improving endurance performance and for stimulating lipocatabolism | |
| US20070092501A1 (en) | Compositions and methods relating to reduction of symptoms of autism | |
| US20020128184A1 (en) | Ubiquinone composition and methods related thereto | |
| KR100520408B1 (en) | Compositions for the improvement of obesity | |
| CN108208417A (en) | Pet anti-oxidant nutritional agents and preparation method thereof | |
| Han et al. | A water extract of Artemisia capillaris prevents 2, 2'-azobis (2-amidinopropane) dihydrochloride-induced liver damage in rats | |
| CN109805391A (en) | A kind of whitening food formulation and its instructions of taking containing tablet and capsule dual dosage form | |
| KR20030077902A (en) | Composition of anti-diabetes patient food using silkworm product | |
| Lonsdale et al. | Thiamine metabolism in disease | |
| KR100606553B1 (en) | Functional beverage composition for improving concentration, learning and memory | |
| KR20150015164A (en) | Dichloromethane or hexan fraction of Orostachys japonicus with antioxidant activity and use thereof | |
| JP2005082495A (en) | Composition for protecting brain cells | |
| JP7620270B2 (en) | Mitochondrial function activator | |
| Jegede et al. | Evaluation of nutritional and therapeutic effects of defatted Moringa oleifera seeds in protein energy malnourished rats | |
| KR0148462B1 (en) | Preparation process of brainactivating soft capsule | |
| KR100522253B1 (en) | Food compositions for the improvement of obesity | |
| Gokulakrishnan et al. | Regenerating activity of Citrus aurantifolia on paracetamol induced heaptic damage. | |
| KR20250075974A (en) | Enzyme mixture composition having high digestibility, antioxidation and anticancer activity and use thereof | |
| KR20250077440A (en) | Dietary supplement for alleviating oxidative stress caused by exercise containing HENKIV® | |
| Franco et al. | Antioxidant Action of Phytochemicals | |
| Fougere | The nutritional implications and associations of vitamin C deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20020327 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040527 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050127 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040527 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20050201 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |